tbuckley/cabot-search huggingface dataset:
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Authors: R. Pinyol, R. Montal, T. Takayama, G.-Y. Chau, V. Mazzaferro, S. Roayaie, H.C. Lee, R.T.-P. Poon, N. Kokudo, Z. Zhang, L. Bassaganyas, S. Torrecilla, A. Moeini, L. Rodriguez-Carunchio, E. Gane, C. Verslype, A.E. Croitoru, U. Cillo, M. de la Mata, L. Lupo, S. Strasser, J.-W. Park, J. Camps, M. Solé, S.N. Thung, A. Villanueva, C. Pena, G. Meinhart, J. Bruix, J.M. Llovet
Journal: Journal of Hepatology (2017)
High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 &amp; 2)
Authors: L. Serfaty, S. Pianko, Z.B. Ari, A.L. Laursen, J. Hansen, E.J. Gane, H.-C. Huang, S. Jin, J. Bourque, H. Liu, A. Grandhi, M. Su, N. Gendrano, D. Fernsler, F. Dutko, B.-Y.T. Nguyen, J. Wahl, E. Barr, W. Yeh, R. Plank, J.R. Butterton
Journal: Journal of Hepatology (2017)
Fractalkine-CX3CR1 is the only predictor for mortality in hepatocellular carcinoma patients treated with curative radiofrequency ablation
Authors: W. Teng, W.-J. Jeng, W.-T. Chen, Y.-C. Hsieh, C.-H. Huang, C.-C. Lin, S.-M. Lin, Y.-C. Chen, C.-Y. Lin, I-S. Sheen
Journal: Journal of Hepatology (2017)
Successful Hepatitis C treatment with direct acting antivirals leads to a rapid on-treatment decrease of liver stiffness with a slower gradual decrease of spleen stiffness
Authors: W. Verlinden, I. Colle, D. Sprengers, J. Van Dongen, L. Vonghia, T. Vanwolleghem, P. Michielsen, S. Francque
Journal: Journal of Hepatology (2017)
Identification of genomic imbalances in methotrexate-resistant human osteosarcoma cell lines
Authors: Massimo Serra, Claudia M. Hattinger, Michela Pasello, Daniel Remondini, Gastone C. Castellani, Giuseppina Stoico, Stefania Benini, Maria C. Manara, Katia Scotlandi, Piero Picci
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

598 

Methotrexate (MTX) is one of the most important drugs for osteosarcoma (OS) treatment. To identify genetic aberrations associated with the development of MTX resistance in OS cells, in addition to the previously reported expression changes of dihydrofolate reductase (DHFR) and reduced folate carrier (RFC) genes, comparative genomic hybridization (CGH)-based techniques were used. The direct comparison between MTX-resistant variants of U-2OS or Saos-2 human OS cell lines with their respective parental cell lines by CGH on chromosomes revealed that in U-2OS variants gain of the chromosomal regions 5q12-q15 and 11q14-qter, and in Saos-2 variants gain of 8q22-qter and loss of 10p were associated with development of MTX resistance. For a higher-resolution DNA profiling of MTX-resistant variants compared to their parental MTX-sensitive cell lines, CGH was performed on DNA microarrays (GenoSensor Array300; Abbott-Vysis), which contained 287 genes known to be frequently amplified or deleted in human cancers. In U-2OS MTX-resistant variants, genes in the chromosomal regions 5q (DHFR, MSH3) and 11q (MLL) were increasingly amplified in association with higher degrees of resistance to MTX. In Saos-2 MTX-resistant variants, genes in the chromosomal region 8q (EXT1, MYC) were amplified, whereas all genes of the region 10p were deleted. Among the genes found to be gained by CGH on microarrrays, DHFR, MLL and MYC were studied by fluorescence in situ hybridization on interphase nuclei. Increased copy numbers of these genes in association with higher resistance levels to MTX were detected and confirmed the data obtained on microarrays. Additional analyses of DHFR, MLL, MYC, and RFC gene status in four human OS cell lines revealed that only gain of DHFR and MLL were associated with an inherent lower sensitivity to MTX. These data indicate, that genes underlying the MTX-resistant phenotype of human OS cells, cluster in certain chromosomal regions. Therefore, analyses of these portions of the human genome and the genes so far identified, DHFR, MLL and MYC, might reveal a set of candidate genes to identify osteosarcoma patients with a lower sensitivity to MTX.
MIV-802, a uridine nucleotide prodrug, is a more potent inhibitor of hepatitis C virus genotype 3 replication than sofosbuvir
Authors: E. Lana, E. Brenndörfer, H. Kylefjord, A. Eneroth, P. Pinho, Å. Rosenquist, P. Targett-Adams, R. Bethell
Journal: Journal of Hepatology (2017)
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen
Authors: M.-F. Yuen, K. Liu, H.L. Chan, B.D. Given, T. Schluep, J. Hamilton, C.-L. Lai, S.A. Locarnini, J.Y. Lau, C. Ferrari, R.G. Gish
Journal: Journal of Hepatology (2017)
Abstract 177: Overexpression of Cardiac Troponin I-Interacting Kinase, a Cardiac-Specific MAPKKK, Promotes Cardiac Dysfunction
Authors: Hao Tang, Kunhong Xiao, Lan Mao, Howard A Rockman, Douglas A Marchuk
Journal: Circulation Research (2012)

Cardiac Troponin I-interacting kinase (TNNI3K) is a cardiac specific kinase whose biological function remains largely unknown. We have recently shown that TNNI3K expression greatly accelerates cardiac dysfunction in mouse models of cardiomyopathy, indicating an important role in modulating disease progression. To further investigate TNNI3K kinase activity in vivo, we have generated transgenic mice expressing both wild-type and kinase-dead versions of the human TNNI3K protein. Importantly, we show that the increased TNNI3K kinase activity induces mouse cardiac hypertrophy, and the kinase activity is required to accelerate disease progression in a left-ventricular pressure overload model of mouse cardiomyopathy. We demonstrate the clinical relevance of these observations by identifying two potential missense mutations near the kinase activation loop of TNNI3K in idiopathic dilated cardiomyopathy (DCM) human patients. Using an in vitro kinase assay and proteomics analysis, we show that TNNI3K is a dual-function kinase with Tyr and Ser/Thr kinase activity. Using antisera to TNNI3K, we show that TNNI3K protein is located at the sarcomere Z disc. These combined data suggest that TNNI3K mediates cell signaling to modulate cardiac response to stress. The essential role of the kinase activity makes TNNI3K a strong potential pharmaceutical target of kinase inhibitors for heart disease.
KLRG1 impairs antiviral immunity of NK-cell in Individuals with Chronic Hepatitis B Virus Infection via the Akt pathway
Authors: M.-H. Li, W.-W. Yin, Q.-F. Zhang, Q. Liu, Y.-L. Li, J.-Y. Shao, H.-D. Hu, H. Ren, P. Hu, D.-Z. Zhang
Journal: Journal of Hepatology (2017)
Drop of FGF19 levels in patients with HCC development following DAA therapy for chronic hepatitis C
Authors: V. Stadlbauer, B. Schmerböck, B. Leber, M. Kipperer, P. Stiegler, A. Posch, A. Streit, W. Spindelböck, P. Fickert, R. Stauber
Journal: Journal of Hepatology (2017)
Post-maturation apoptosis of retinoid-insensitive myeloid blast cells by rexinoid-PKA crosstalk.
Authors: E M Schiavone, L Altucci, A Rossin, E Wilhelm, Fabien Guidez, David Grimwade, A Zelent, F Ferrara, M De Simone, P Bontempo, H Gronemeyer
Journal: Blood (2002)
Arteriovenous Malformations of the Brain
Authors: Robert A. Solomon, E. Sander Connolly
Journal: New England Journal of Medicine (2017)

Cerebral hemorrhage and seizures are the main complications of cerebral arteriovenous malformations. The choice of surgery, embolization, or radiosurgery for the treatment of these lesions is made by considering the lesion size, vascular anatomy, and brain region involved.
A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis
Authors: R. Moreau, L. Elkrief, C. Bureau, J.-M. Pérarnau, T. Thévenot, F. Saliba, A. Louvet, P. Nahon, F. Oberti, R. Anty, S. Hillaire, B. Pasquet, V. Ozenne, M. Rudler, I. Ollivier-Hourmand, M.-A. Robic, L. D’Alteroche, V. Di Martino, P.-E. Rautou, N. Gault, D. Lebrec
Journal: Journal of Hepatology (2017)
In vivo retention of poloxamer-based in situ hydrogels for vaginal application in mouse and rat models
Authors: Yu Liu, Fujin Yang, Linglin Feng, Long Yang, Lingyun Chen, Gang Wei, Weiyue Lu
Journal: Acta Pharmaceutica Sinica B (2017)

The purpose of this study is to evaluate the in vivo retention capabilities of poloxamer-based in situ hydrogels for vaginal application with nonoxinol-9 as the model drug. Two in situ hydrogel formulations, which contained 18% poloxamer 407 plus 1% poloxamer 188 (GEL1, relative hydrophobic) or 6% poloxamer 188 (GEL2, relative hydrophilic), were compared with respect to the rheological properties, in vitro hydrogel erosion and drug release. The vaginal retention capabilities of these hydrogel formulations were further determined in two small animal models, including drug quantitation of vaginal rinsing fluid in mice and isotope tracing with 99mTc in rats. The two formulations exhibited similar phase transition temperatures ranging from 27 to 32 °C. Increasing the content of poloxamer 188 resulted in higher rheological moduli under body temperature, but slightly accelerated hydrogel erosion and drug release. When compared in vivo, GEL1 was eliminated significantly slower in rat vagina than GEL2, while the vaginal retention of these two hydrogel formulations behaved similarly in mice. In conclusion, increases in the hydrophilic content of formulations led to faster hydrogel erosion, drug release and intravaginal elimination. Rats appear to be a better animal model than mice to evaluate the in situ hydrogel for vaginal application.
Small ubiquitin-like modifier protein-specific protease 3 de-SUMOylates NR4A2 protein and controls lipid metabolism in non-alcoholic fatty liver disease
Authors: Y. Liu, Z. Cao, X. Wang, R. Mo, P. Ren, L. Chen, X. Xiang, H. Wang, W. Cai, Q. Li, J. Lu, Q. Xie
Journal: Journal of Hepatology (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Authors: Laxmi Silwal-Pandit, Silje Nord, Hedda von der Lippe Gythfeldt, Elen K. Møller, Thomas Fleischer, Einar Rødland, Marit Krohn, Elin Borgen, Øystein Garred, Tone Olsen, Phuong Vu, Helle Skjerven, Anne Fangberget, Marit M. Holmen, Ellen Schlitchting, Elisabeth Wille, Mette Nordberg Stokke, Hans Kristian Moen Vollan, Vessela Kristensen, Anita Langerød, Steinar Lundgren, Erik Wist, Bjørn Naume, Ole Christian Lingjærde, Anne-Lise Børresen-Dale, Olav Engebraaten
Journal: Clinical Cancer Research (2017)

Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab.Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm. Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks). Pathologic complete response (pCR) in breast and axillary nodes was the primary endpoint.Results: pCR was observed in 15 patients (23%) receiving bevacizumab and chemotherapy and 8 patients (12%) receiving only chemotherapy. In the estrogen receptor-positive patients, 11 of 54 (20%) treated with bevacizumab and chemotherapy achieved pCR, while only 3 of 57 (5%) treated with chemotherapy reached pCR. In patients with estrogen receptor-positive tumors treated with combination therapy, an elevated immune activity was associated with good response. Proliferation was reduced after treatment in both treatment arms and most pronounced in the combination therapy arm, where the reduction in proliferation accelerated during treatment. Transcriptional alterations during therapy were subtype specific, and the effect of adding bevacizumab was most evident for luminal-B tumors.Conclusions: Clinical response and gene expression response differed between patients receiving combination therapy and chemotherapy alone. The results may guide identification of patients likely to benefit from antiangiogenic therapy. Clin Cancer Res; 23(16); 4662-70. ©2017 AACR.
Price migration of oncology drugs launched in the United States between 2010 and 2015.
Authors: Alex Bastian, Jessica Li, Akwasi Asabere
Journal: Journal of Clinical Oncology (2015)

6606 Background: As discussions of value increasingly enter the oncology arena, the price, or cost, of drugs is becoming increasingly relevant. Here, we have reviewed new cancer drugs launches in the USA to characterize the level, nature, and extent of price migrations taken by manufacturers Methods: FDA approvals (N = 158) between 2010 and 2015 were obtained from the FDA website, from which all non-oncology drugs (n = 119) were excluded. The remaining list (n = 39) included only oncology drugs. The Wholesale Acquisition Cost (WAC) prices at launch, and subsequent price increases, for these products were then extracted from AnalySource, a web-based analytical drug pricing database. We evaluated compound annual growth rate (CAGR), interval periods, and frequency of price increases of these agents. Further analysis identified potential distinctions across tumor types, route of administration (ROA), and other related features Results: The mean CAGR was 5.9%, ranging from 0% to 33.7%. Price increases occurred an average of 2.3 times at a mean interval of 11.1 months, ranging from 7 to 27 months. Notably, twelve of drugs did not increase in price. Only three drugs increased their price within 6 months of market entry, and 50% did so by month 23. Solid tumor price migration was higher than for hematologic malignancies (6.6% vs. 4.7%, respectively). The highest increase was seen within lung cancer (13.3%), with gastric and ovarian cancer showing no increase. ROA also had an important impact, with oral drugs demonstrating higher price migrations than injectable drugs (8.3% vs. 3.4%) Conclusions: The results of our analysis show important differences in the magnitude and frequency of price increases taken by oncology drug manufacturers. Differences are seen by tumor type and by ROA. Further inquiry may be useful to determine the structural and strategic factors driving these differences. CAGR (%) Injectable Oral All Solid Tumors 4.4% 8.5% 6.6% Lung 13.3% 13.3% Prostate 12.4% 7.8% 10.6% Thyroid 7.5% 7.5% Colorectal 5.1% 5.1% Skin 0.6% 6.8% 4.2% Breast 1.1% 1.1% Other 0.0% 3.6% 2.4% Hematological 1.7% 8.1% 4.7% CLL 0.0% 17.6% 8.8% Lymphoma 3.3% 5.6% 4.1% CML 0.0% 6.1% 4.0% MM 1.7% 4.5% 3.1% Other 1.9% 8.7% 4.1% All 3.4% 8.3% 5.9%
Treatment of <i>KRAS-</i>Mutant Non–Small Cell Lung Cancer
Authors: Jacob Kaufman, Thomas E. Stinchcombe
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heating of membrane rafts of cancer-cells.
Authors: Oliver Szasz, Gabor Andocs, Takashi Kondo, Mati Ur Rehman, Edina Papp, Tamas Vancsik, Tibor Krenacs
Journal: Journal of Clinical Oncology (2015)

e22176 Background: Heating by nanoparticles is a well-recognized method in hyperthermic oncology. Our aim is to present a possibility of selective nanoscopic heating without administration of artificial nanoparticles, targeting the clusters of transmembrane proteins of malignant cells. Methods: The technology (called modulated electro-hyperthermia, mEHT) is impedance controlled capacitive coupling. It is impedance matched; time-fractal amplitude modulated radiofrequency treatment. The nano-selection is based on the certain deviations of metabolic-processes of cellular-connections and of organizing-pattern of malignant cells from their healthy counterparts. The cell-killing mechanism is connected to the intensive but very local nano-range energy absorption which is selectively delivered by electrodynamic conditions. The thermal effects were measured by the well-known Arrhenius-plot, and conventional hyperthermia was used as reference. There were various in-vitro and in-vivo measurements evaluated by cell-counting and immunohistochemical methods. Results: We showed in-silico the selective and extreme large energy-absorption by membrane rafts. Measurements show definitely 3+ºC advantage of mEHT calibrated on conventional heating (cHT). The measured apoptotic processes [1] and the damage associated molecular pattern (DAMP) concluding to immunogenic cell-death (ICD) [2] are presumed as the consequence of the membrane modifications by electromagnetic interactions. The measured temperature shift of the effects of cell-destruction clearly explains the earlier in-vivo observations [3]. Conclusions: Certain cell-membrane associated destruction is reached by mEHT at least at 3ºC less temperature than by cHT, inducing DAMP and ICD. We assume that this difference is the consequence of the selective heating of the clusters of the transmembrane proteins which is in fact a non-artificial nanoparticle heating. Reference [1] Meggyeshazi N. et.al. Strahlenther Onkol, 2014, 190:815-822 [2] Andocs G. et.al. Cell Stress and Chaperones, 2015, 20(1):37-46 [3] Andocs G. et.al. J Rad. Oncol, Biol, Phys. 2009, 185(2):120-6
Genetics of medullary thyroid cancer: An overview
Authors: Giacomo Accardo, Giovanni Conzo, Daniela Esposito, Claudio Gambardella, Marco Mazzella, Filomena Castaldo, Carlo Di Donna, Andrea Polistena, Nicola Avenia, Vittorio Colantuoni, Dario Giugliano, Daniela Pasquali
Journal: International Journal of Surgery (2017)
Survival in patients with metastatic prostate cancer in Peru.
Authors: Teofilo Livano Yberico, Brady Ernesto Beltran, Jorge J. Castillo
Journal: Journal of Clinical Oncology (2014)

e16110 Background: To determine the factors associated with average length of total androgen blockade (TAB) response and overall survival (OS) in newly diagnosed patients with metastatic prostate cancer (MCP) in a general hospital in Peru. Methods: This is an observational, retrospective and cross-sectional study. Fifty-four patients newly diagnosed with MCP who were treated at the Central Military Hospital during the period of January 2000 through December 2007 were reviewed. Length of TAB was defined as use of LHRH analog or orchiectomy + / - antiandrogen ,Overall survival was defined as the number of months of survival from diagnosis to death. Results: The median age at diagnosis was 74 years (range: 51-88 years). Following diagnosis, 21 patients (39%) received medical TAB and 44 (61%)underwent orchiectomy. Gleason scores of ≤6, 7 and ≥8 were seen in 26 (48%), 15 (28%) and 13 patients (24%), respectively, and 18 (33%), 19 (35%) and 17 patients (31%) had a total PSA of <50, 50-100 and >100 ng/ml, respectively. The median duration of response to TAB was 46 months (range: 9-85 months) and the median OS was 52 months (range: 12-99 months). According to Gleason scores of ≤6, 7, ≥8, response duration to TAB was 53, 45 and 23 months, respectively (Log-rank p<0.05). According to total PSA value <50, 50-100 and >100 ng/ml, the median duration of response to TAB was 56, 33 and 31 months, respectively (p<0.05). According to Gleason scores of ≤6, 7, ≥8, the median OS was 61, 58 and 28 months, respectively (p<0.05), and according to total PSA value <50, 50-100 and >100 ng/ml, the median OS was 63,38 and 36 months respectively (p<0.05). Conclusions: The Gleason score and the total PSA value at diagnosis were factors associated with duration of response to TAB and OS in Peruvian patients newly diagnosed with MPC. Survival data is similar to asiatic casuistry.
Influence of UCP3 gene polymorphisms on metabolic syndrome and cardiovascular risk in patients with in non-alcoholic fatty liver disease
Authors: K.S. Toda, J.T. Stefano, F.B. Costa, A.M. Cavaleiro, D.F. Mazo, F.J. Carrilho, M.L. Correa-Giannella, C.P. Oliveira
Journal: Journal of Hepatology (2017)
CCL2-dependent monocyte recruitment contributes to a tumor-promoting microenvironment in a combined fibrosis-HCC model
Authors: P.L. Schrammen, M. Bartneck, D. Möckel, A. Liepelt, D. Eulberg, T. Longerich, T. Lüdde, C. Trautwein, T. Lammers, F. Tacke
Journal: Journal of Hepatology (2017)
Utility of serum alpha-fetoprotein measurement with a cutoff of 20 ng/mL in addition to ultrasound surveillance for hepatocellular carcinoma in patients with chronic hepatitis B - a regression discontinuity analysis
Authors: Y.-Z.D. Lim, H.-K. Koh, J.-X.J. Lim, C.-K. Tan
Journal: Journal of Hepatology (2017)
Revisit HBsAg for HBeAg-negative chronic hepatitis B undergoing peginterferon treatment: a multicenter pooled-analysis study
Authors: Y.C. Wang, C.-Y. Peng, S.-S. Yang, C.-W. Su, Y.-J. Wang, M.-C. Hou, H.-C. Lin, Y.-H. Huang
Journal: Journal of Hepatology (2017)
Performance of upper gastrointestinal bleeding risk assessment scores in variceal bleeding: a prospective international multicenter study
Authors: J.H. Ngu, S.B. Laursen, Y.K. Chin, L. Laine, H.R. Dalton, I.A. Murray, M. Schultz, N.V. Nadkarni, A.J. Stanley
Journal: Journal of Hepatology (2017)
Prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders
Authors: A. Parfieniuk-Kowerda, J. Pogorzelska, T.W. Lapinski, M. Maciaszek, M. Swiderska, A. Grzeszczuk, B. Naumnik, M. Rowiński, J. Jaroszewicz, R. Flisiak
Journal: Journal of Hepatology (2017)
Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial
Authors: A. Horvath, M. Bashir, B. Schmerboeck, F. Rainer, E. Krones, F. Baumann-Durchschein, P. Douschan, W. Spindelboeck, G. Zollner, R.E. Stauber, P. Fickert, P. Stiegler, B. Leber, V. Stadlbauer
Journal: Journal of Hepatology (2017)
A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH
Authors: S. Harrison, E. Praca, J. Brozek, G. Cordonnier, F.B. Sudrik, A. Roudot, P. Bedossa, V. Ratziu, B. Staels, D. Hum, S. Megnien, P. Chaumat, R. Hanf, A. Sanyal
Journal: Journal of Hepatology (2017)
Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study
Authors: M. Khalili, T.M. Welzel, J.K. Lim, G.A. Lutchman, D.R. Nelson, B. Borg, A.S. Lok, A. Ramani, N. Reau, M. Vainorius, M.W. Fried, C.S. Landis
Journal: Journal of Hepatology (2017)